Key Highlights
- Dr. Mohamed Donia’s appointment as CSO and Scientific Co-founder at Pragma Bio, emphasizing his two decades of expertise in natural product discovery.
- Groundbreaking scientific achievements in identifying novel small molecules and biochemical pathways, with a focus on the gut-immune axis.
- Pragma Bio’s strategic vision for drug development, leveraging Dr. Donia’s experience in building collaborations with top-tier biopharmaceutical companies.
Source: Business Wire
Notable Quotes
- “Dr. Donia’s deep domain expertise has been instrumental in advancing our understanding of how small molecules within humans can lead to better starting points for therapeutics.” – Dr. Grazia Piizzi, expert drug discovery leader and a pharma executive
- “I am excited to embark on this new journey with Pragma Bio, a company at the forefront of drug discovery.” – Dr. Mohamed Donia, CSO at Pragma Bio
SoH's Take
The appointment of Dr. Mohamed Donia as the CSO and Scientific Co-founder at Pragma Bio marks a significant milestone in the biotech startup’s journey. Dr. Donia’s extensive experience in natural product discovery and his history of successful collaborations in the biopharmaceutical sector position him uniquely to drive Pragma Bio’s mission in small molecule drug discovery. His focus on the gut-immune axis and other therapeutic indications aligns well with the current trends in drug development, promising innovative approaches in the field. This strategic move is likely to accelerate Pragma Bio’s growth trajectory and reinforce its standing in the competitive landscape of drug discovery and development.
